Panitumumab rechallenge in chemorefractory patients with metastatic colorectal cancer

Journal of Gastrointestinal Cancer

Volumn 44, Issue 4, 2013, Pages 456-459

  Hata, Akito ^a   Katakami, Nobuyuki ^a   Fujita, Shiro ^a   Takatori, Kento ^b   Horai, Aya ^b   Kitajima, Naoto ^b   Terashima, Kazuki ^b  

^a INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^b Kasai City Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BILIRUBIN; CAPECITABINE PLUS OXALIPLATIN; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; K RAS PROTEIN; LIVER ENZYME; MITOMYCIN; OXALIPLATIN; PANITUMUMAB; STARCH MICROSPHERE;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CASE REPORT; COLON RESECTION; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG RECHALLENGE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OUTPATIENT DEPARTMENT; PARONYCHIA; PRIORITY JOURNAL; RASH; THORAX RADIOGRAPHY; TREATMENT DURATION;

AGED; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SALVAGE THERAPY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84888204094     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-012-9453-7     Document Type: Article

References (15)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42.
3. Saltz LB, Clarke S, Diaz Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-9.
4. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663-71.
5. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as firstline treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697-705.
6. Santini D, Vincenzi B, Addeo R, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol. 2012;23:2313-8.
7. Saif MW, Kaley K, Chu E, et al. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Clin Colorectal Cancer. 2010;9:315-8.
8. Power DG, Shah MA, Asmis TR, et al. Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience. Investig New Drugs. 2010;28:353-60.
9. Heun J, Holen K. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin Colorectal Cancer. 2007;6:529-31.
10. Langerak A, River G, Mitchell E, et al. Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports. Clin Colorectal Cancer. 2009;8:49-54.
11. Tomizawa Y, Fujita Y, Tamura A, et al. Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy. Lung Cancer. 2010;68:269-72.
12. Hata A, Katakami N, Yoshioka H, et al. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection. Lung Cancer. 2011;74:268-73.
13. Townsend AR, Bishnoi S, Broadbridge V, et al. Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy. Am J Clin Oncol. 2012; in press
14. Santini D, Vincenzi B, La Cesa A, et al. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil and irinotecan-resistant advanced colorectal cancer patients. Oncology. 2005;69:27-34.
15. Grothey A, Cutsem EV, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multi center, randomized, placebo-controlled, phase 3 trial. Lancet. 2012; in press